Core Viewpoint - The article discusses the effectiveness, safety, and usage guidelines of Semaglutide, a GLP-1 receptor agonist, for weight loss and its implications for patients with obesity and related comorbidities [5]. Weight Loss Efficacy - In the OASIS 1 study, patients taking oral Semaglutide 50mg lost an average of 17.4% (18.34 kg) of their body weight over 68 weeks [6]. - The OASIS 4 study showed that patients taking oral Semaglutide 25mg lost an average of 13.6% (14.4 kg) over 64 weeks, with potential weight loss reaching 16.6% (17.6 kg) if all participants completed the treatment [7]. Side Effects - Approximately 30% of patients reported gastrointestinal side effects such as nausea, vomiting, and diarrhea, which were mostly mild to moderate and tended to resolve over time [8]. - Semaglutide has shown good safety in elderly patients and those with renal impairment, although caution is advised for patients with severe renal dysfunction [8][9]. Usage Guidelines - Semaglutide should be taken at least 30 minutes before the first meal of the day, using no more than 118ml of plain water for swallowing [10]. - The starting dose is recommended at 3mg once daily for 30 days, followed by an increase to 7mg once daily, with a maximum dose of 14mg if necessary [12][13]. Lifestyle Changes - Weight loss should not solely focus on dieting; a balanced diet with adequate protein intake and regular physical activity is essential [15][18]. - The article emphasizes the importance of not consuming fewer than 1200 calories daily and suggests a "small meals" approach to avoid binge eating [15][17]. Mechanism of Action - Semaglutide lowers blood sugar through a glucose-dependent mechanism, improving beta-cell function and insulin resistance while suppressing glucagon secretion [19]. - It mimics GLP-1 to regulate appetite and prolong satiety by slowing gastric emptying [20][21]. Other Therapeutic Effects - Semaglutide has been shown to significantly lower blood sugar levels and has additional benefits such as weight loss, blood pressure reduction, and lipid regulation [29]. - In the PIONEER 6 study, it demonstrated a 51% reduction in cardiovascular death risk compared to placebo in patients with type 2 diabetes and cardiovascular risk factors [30]. Advantages of Oral Formulation - The oral formulation of Semaglutide is easier to store and transport compared to injectable forms, which require strict cold chain logistics [31][32]. - It is also more convenient for patients who may have a fear of injections [33]. Risk of Hypoglycemia - Semaglutide's glucose-dependent mechanism means it does not cause hypoglycemia in individuals with normal blood sugar levels, making it a safer option for weight loss [34]. Weight Regain After Discontinuation - A study indicated that 18% of patients regained weight after stopping Semaglutide, while 56% maintained or continued to lose weight [35].

Core Viewpoint - The article addresses common questions regarding the oral semaglutide for weight loss, emphasizing its effectiveness, usage guidelines, and safety profile. Group 1: Weight Loss Efficacy - In the OASIS 1 study, participants using 50mg oral semaglutide lost an average of 17.4% (18.34 kg) of their body weight over 68 weeks [2] - The OASIS 4 study showed that participants using 25mg oral semaglutide lost an average of 13.6% (14.4 kg) over 64 weeks, with potential maximum weight loss reaching 16.6% (17.6 kg) if all subjects completed the treatment [4] - To achieve weight loss effects similar to the injectable version, higher doses of oral semaglutide (up to 25mg or 50mg) may be required, while the current maximum available dose is 14mg [4] Group 2: Side Effects and Safety - Approximately 30% of participants reported gastrointestinal side effects such as nausea, vomiting, and diarrhea, which are common with GLP-1 receptor agonists [5] - Semaglutide has shown good safety in elderly patients and those with renal impairment, but caution is advised for patients with severe renal dysfunction [7] - Long-term safety data is still being collected, but current studies indicate good long-term tolerability [8] Group 3: Usage Guidelines - Semaglutide should be taken at least 30 minutes before the first meal of the day, using no more than 118ml of plain water for swallowing [9] - The recommended starting dose is 3mg once daily for 30 days, followed by an increase to 7mg once daily [11][12] - If the 7mg dose is ineffective after 30 days, it can be increased to a maximum of 14mg once daily [13] Group 4: Lifestyle Changes for Weight Loss - The article emphasizes that weight loss should not solely focus on calorie restriction; a balanced diet with a minimum of 1200 kcal daily is recommended [15] - Adequate protein intake of at least 1g per kg of body weight is essential, and caloric deficits should be maintained within 300-500 kcal [17] - Regular physical activity is crucial, with recommendations for 150-300 minutes of moderate-intensity exercise weekly [18] Group 5: Mechanism of Action - Semaglutide lowers blood sugar through a glucose-dependent mechanism, improving beta-cell function and insulin resistance [19] - It mimics GLP-1 to help control appetite and prolong satiety by slowing gastric emptying [20][21] Group 6: Additional Benefits - In the PIONEER study, semaglutide demonstrated efficacy in managing type 2 diabetes, significantly lowering HbA1c levels in 92.3% of newly diagnosed patients [28] - The PIONEER 6 study indicated a 51% reduction in cardiovascular death risk among type 2 diabetes patients using semaglutide [29] Group 7: Advantages of Oral Formulation - Oral semaglutide can be stored at room temperature, making it easier to transport compared to injectable forms that require cold chain storage [31] - The oral formulation is more convenient for patients who may fear injections [33] Group 8: Risk of Hypoglycemia - Semaglutide's glucose-dependent mechanism means it does not induce hypoglycemia in individuals with normal blood sugar levels, making it safer for weight loss treatment [34] Group 9: Weight Regain After Discontinuation - In a study, 18% of patients regained weight after stopping semaglutide, while 26% regained more than 25% of their lost weight, indicating a potential for weight rebound [35]